Brief: Algernon Pharmaceuticals Announces It Will Not Advance Ifenprodil Into Phase 3 Trial For Covid-19

Grey Matters Health

06/07/2021 13:45

July 6 (Reuters) - Algernon Pharmaceuticals Inc  AGN.CD :
    * ALGERNON PHARMACEUTICALS ANNOUNCES IT WILL NOT ADVANCE
IFENPRODIL INTO PHASE 3 TRIAL FOR COVID-19
    * ALGERNON PHARMACEUTICALS INC - DECISION WAS BASED ON
SEVERAL
FACTORS INCLUDING OVERALL FINDINGS OF PHASE 2B COVID-19 STUDY
FINAL DATA SET
    * ALGERNON PHARMACEUTICALS - FEEDBACK RECENTLY RECEIVED FROM
FDA
REGARDING CO'S END OF PHASE 2 MEETING REQUEST WAS ALSO
INFORMATIVE
    * ALGERNON PHARMACEUTICALS - DECISION WILL NOT AFFECT ANY
OTHER
RESEARCH PROGRAMS INCLUDING INVESTIGATING IFENPRODIL FOR OTHER
DISEASE INDICATIONS

Source text for Eikon:  ID:nGNX92mdjF 
Further company coverage:  AGN.CD 

 ((Reuters.Briefs@thomsonreuters.com;))